ASCO GU 2022: Reflecting on RCC Data With Drs. Toni Choueiri and Peter Van Veldhuizen
OncLive® speaks with Drs. Toni Choueiri and Peter Van Veldhuizen on the latest studies in renal cell carcinoma that were presented during the 2022 Genitourinary Cancers Symposium.
EP: 1.ASCO GU 2022: Piecing Together Prostate Cancer Data With Drs. Tanya Dorff and Jathin Bandari
EP: 2.ASCO GU 2022: Breaking Down Bladder Cancer Results With Drs. Jonathan Rosenberg and Guru Sonpavde
EP: 3.ASCO GU 2022: Reflecting on RCC Data With Drs. Toni Choueiri and Peter Van Veldhuizen
Today-
We are reporting from the 2022 Genitourinary Cancers Symposium!
Get ready for highlights of some of the top news presented each day during the meeting—and soon Drs Toni Choueiri and Peter Van Veldhuizen will be with us to share some riveting results in renal cell carcinoma.
Welcome to OncLive News Network! I’m Gina Mauro.
Adjuvant pembrolizumab continued to demonstrate a consistent and clinically meaningful improvement in disease-free survival vs placebo in patients with renal cell carcinoma who were at high risk of recurrence, according to 30 months of follow-up of the phase 3 KEYNOTE-564 trial.
An East Asian subset of the phase 3 CLEAR trial showed that the combination of pembrolizumab and lenvatinib also showed consistent efficacy and safety data with this subgroup compared with the overall population of patients with advanced renal cell carcinoma.
Immune cell-related parameters, including higher percentages of blood-circulating 4-1BB+ CD4+ T cells and LAG3+ CD4+ T cells, were found to be associated with increased therapeutic efficacy with the combination of nivolumab and ipilimumab in clear cell RCC. These parameters, which were studied in the phase 2 TITAN-RCC trial, may represent novel predictive biomarkers for response.
In the single-arm, phase 2 NeoAvAx trial, neoadjuvant avelumab plus axitinib was found to lead to clinical responses in patients with non-metastatic high-risk renal cell carcinoma.
Long-term follow-up from the phase 3 TIVO-3 trial showed that patients with relapsed/refractory renal cell carcinoma were 5 times more likely to experience long-term PFS compared with sorafenib. Investigators noted that a clinically relevant minority of patients are alive and progression-free on tivozanib at 3- and 4-years.
Please be sure to check out more of our coverage from the 2022 ASCO GU meeting at OncLive.com.
That’s all for today. Thank you for watching OncLive News Network: On Location. Signing off from the 2022 Genitourinary Cancers Symposium, I’m Gina Mauro.
